BackgroundDepending on the treatment to be investigated, a clinical trial could be designed to assess objectives of superiority, equivalence or non-inferiority. The design of the study is affected by many different elements including the control treatment, the primary outcome and associated relationships. In some studies, there could be more than one outcome of interest. In these situations, benefit-risk methodologies could be used to assess the outcomes simultaneously and consider the trade-off between the benefits against the risks of a treatment. Benefit-risk is used within the regulatory industry but seldom included within publicly funded clinical trials within the UK. This project aims to gain an expert consensus on how to select the a...
Currently, regulators make marketing authorisation decisions based on the benefit-risk balance of a ...
Background: This study examined the assessment of risk/benefit ratios for phase II cancer clinical t...
Background: The main responsibility of regulators and industry is to ensure the benefit-risk balance...
Background Depending on the treatment to be investigated, a clinical trial could be designed to asse...
Background Depending on the treatment to be investigated, a clinical trial could be designed to asse...
PURPOSE: Difficulties may be encountered when undertaking a benefit-risk assessment for an older pro...
Objectives: There are indications that institutional review board (IRB) members do not find it easy ...
Benefit-risk assessment is the cornerstone of decision making in medical care, playing a critical ro...
Benefit–risk assessment in medicine has been a valuable tool in the regulation of medicines since th...
BACKGROUND: The need for formal and structured approaches for benefit-risk assessment of medicines i...
BACKGROUND: The need for formal and structured approaches for benefit-risk assessment of medicines i...
Purpose Decisions leading to drug approval demand careful attention with respect to balancing benefi...
In order for a medicinal product to get marketing authorization in Europe, it has to demonstrate a p...
Risk-benefit assessment for decision-making based on evidence is a subject of continuing interest. H...
Assessing the utility of structured approaches to benefit-risk assessment of medicinal products is c...
Currently, regulators make marketing authorisation decisions based on the benefit-risk balance of a ...
Background: This study examined the assessment of risk/benefit ratios for phase II cancer clinical t...
Background: The main responsibility of regulators and industry is to ensure the benefit-risk balance...
Background Depending on the treatment to be investigated, a clinical trial could be designed to asse...
Background Depending on the treatment to be investigated, a clinical trial could be designed to asse...
PURPOSE: Difficulties may be encountered when undertaking a benefit-risk assessment for an older pro...
Objectives: There are indications that institutional review board (IRB) members do not find it easy ...
Benefit-risk assessment is the cornerstone of decision making in medical care, playing a critical ro...
Benefit–risk assessment in medicine has been a valuable tool in the regulation of medicines since th...
BACKGROUND: The need for formal and structured approaches for benefit-risk assessment of medicines i...
BACKGROUND: The need for formal and structured approaches for benefit-risk assessment of medicines i...
Purpose Decisions leading to drug approval demand careful attention with respect to balancing benefi...
In order for a medicinal product to get marketing authorization in Europe, it has to demonstrate a p...
Risk-benefit assessment for decision-making based on evidence is a subject of continuing interest. H...
Assessing the utility of structured approaches to benefit-risk assessment of medicinal products is c...
Currently, regulators make marketing authorisation decisions based on the benefit-risk balance of a ...
Background: This study examined the assessment of risk/benefit ratios for phase II cancer clinical t...
Background: The main responsibility of regulators and industry is to ensure the benefit-risk balance...